{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-012763","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2022-01-20T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.408811+00:00","generated_at":"2026-06-27T16:47:08.023271+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aadi Bioscience enters manufacturing agreement with Fresenius Kabi for Fyarro","bullets":["Fresenius Kabi to manufacture Fyarro (sirolimus protein-bound) for Aadi under a purchase-order basis.","Agreement effective through Dec 31, 2022; covers clinical and commercial supply for US and Canada.","Aadi has minimum purchase obligations; failure triggers additional payment to Fresenius Kabi.","Price fixed but subject to increase under specified circumstances; includes labeling/packaging services."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-012763","json":"https://secwatch.observer/filing/0001193125-22-012763.json","markdown":"https://secwatch.observer/filing/0001193125-22-012763.md","text":"https://secwatch.observer/filing/0001193125-22-012763.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000119312522012763/0001193125-22-012763-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000119312522012763/d295801d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T16:47:08.023271+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}